Quinoline antimalarials

Bibliography

• REPORT OF THE AD HOC COMMITTEE ON HEALTH RE-SEARCH RELATING TO FUTURE INTERVENTION OP-TIONS: Investing in health research and development. World Health Organisation, Geneva (1996).
   Google Scholar
• HOFHEINZ W, MERKLI B: Quinine and quinine ana-logues. In: Handbook of Experimental Pharmacology. Vol. 68/II Antimalarial Drugs II. Peters W, Richards WHG (Eds.), Springer-Verlag (1984) 61–81.
   Google Scholar
• ELLIS JE: Coenzyme Q homologs in parasitic protozoa as targets for chemotherapeutic attack. Parasitol Today 10:296–301 (1994).
   PubMedGoogle Scholar
• GUTTERIDGE WE: Pneumocystis carinii: potential tar-gets for chemotherapeutic attack. In: Biochemical Proto-zoology. Coombs GH, North M (Eds.), Taylor & Francis (1991) 35–51.
   Google Scholar
• SLATER AFG: Chloroquine: mechanism of drug action and resistance in Plasmodium falciparum. Pharmacol Ther. (1993) 57:203–235.
   PubMed Web of Science ®Google Scholar
• EGAN TJ, ROSS DC, ADAMS PA: The mechanism of ac-tion of quinolines and related anti-malarial drugs. South African J ScL (1996) 92:11–14.
   Google Scholar
• RIDLEY RG: Haem polymerisation in malaria parasites. Is there a haem polymerase? Trends Microbial. (1996) 4:253–254.
   PubMed Web of Science ®Google Scholar
• FOLEY M, TILLEY L: Quinoline antimalarials: mecha-nisms of action and resistance. Intern. J. Parasitol. (1997) 27:231–240.
   PubMed Web of Science ®Google Scholar
• DORN A, VIPPAGUNTA SR, MATILE H, JAQUET C, VEN-NERSTROM JL, RIDLEY RG: The binding of quinoline antimalarials to hematin (heme) correlates with inhi-bition of hematin polymerisation and inhibition of P. falciparum growth. Biochem. Pharmacol (In Press).
   Google Scholar
• PANDEY AV, TEKWANI BL: Depolymerization of malar-ial hemozoin: a novel reaction initiated by blood schi-zonticidal antimalarials. FEBS Lett. (1997) 402:236–240.
   PubMed Web of Science ®Google Scholar
• MESHNICK S: Is haemozoin a target for antimalarialdrugs? Ann. Trop. Med. Parasitol (1996) 90:367–372.
   Google Scholar
• COHEN S, PHIFER K, YIELDING K: Complex formationbetween chloroquine and ferrihaemic acid in vitro, and its effect on the antimalarial action of chloro-quine. Nature (1964) 202:805–806.
   PubMed Web of Science ®Google Scholar
• CHOU AC, CHERLI R, FITCH CD: Ferriprotoporphyrin IXfulfills the criteria for identification as the chloro-quine receptor of malaria parasites. Biochemistry (1980) 19:1543–1549.
   PubMed Web of Science ®Google Scholar
• SLATER AFG, CERAMI A: Inhibition by chloroquine of a novel haem polymerase enzyme activity in malaria trophozoites. Nature (1992) 355:167–169.
   PubMed Web of Science ®Google Scholar
• ••Initial report that quinoline blood schizonticides inhibit thepolymerisation of haem into haemozoin/P-haematin. At the time the authors assumed that the haem polymerisation ac-tivity was due to an enzyme.
   Google Scholar
• DORN A, STOFFEL R, MATILE H, BUBENDORF A, RIDLEY RG: Malarial haemozoin/beta-haematin supports haem polymerization in the absence of protein. Nature (1995) 374:269–271.
   PubMed Web of Science ®Google Scholar
• ••A detailed analysis of the haem polymerisation activity fromparasite extracts demonstrating that the process is not enzyme-mediated, but physico-chemical in nature. It was postulated that the quinolines act by binding haem, consis-tent with the earlier hypothesis of Fitch.
   Google Scholar
• SULLIVAN DJ, GLUZMAN IY, GOLDBERG DE: Plasmo-dium hemozoin formation mediated by histidine-rich proteins. Science (1996) 271:219–222.
   PubMed Web of Science ®Google Scholar
• RIDLEY RG, DORN A, VIPPAGUNTA SR, VENNERSTROMJL: Haematin (haem) polymerisation and its inhibition by quinoline antimalarials. Ann. Trop. Med. Parasitol. (1997) 91:559–566.
   PubMed Web of Science ®Google Scholar
• EGAN TJ, MAVUSO W, ROSS DC, MARQUES HM: Thermo-dynamic factors controlling the interaction of quino-line antimalarial drugs with ferriprotoporphyrin IX. J. Inorg. Biochem. (1997) 68:137–145.
   PubMed Web of Science ®Google Scholar
• AIKAWA M: High resolution autoradiography of malar-ial parasites treated with 3H chloroquine. Am. J. Pathol. (1972) 67:277–284.
   PubMed Web of Science ®Google Scholar
• SULLIVAN DJ, GLUZMAN IY, RUSSEL DG, GOLDBERG DE:On the molecular mechanism of chloroquine's anti-malarial action. Proc. Natl. Acad. Sci. USA (1996) 93:11865–11870.
   PubMed Web of Science ®Google Scholar
• BALASUBRAMANIAN D, MOHAN RAO C, PANJIPAN B: Themalaria parasite monitored by photoacoustic spec-troscopy. Science (1984) 223:828–830.
   PubMed Web of Science ®Google Scholar
• HYDE JE: Point mutations and pyrimethamine resis-tance in Plasmodium falciparum. Parasitol. Today (1989) 5:252–255.
   PubMedGoogle Scholar
• WHITE NJ: Antimalarial drug resistance: the pace quickens. J. Antimicrob. Chemother. (1992) 30:571–585.
   PubMed Web of Science ®Google Scholar
• DAVIDSON MW, GLIGGS DG JR, BOYKIN DW, WILSON WD: Mefloquine, a clinically useful quinolinemetha-nol antimalarial which does not significantly bind to DNA. Nature (1975) 254:632–634.
   PubMed Web of Science ®Google Scholar
• WERBEL LM, COOK PD, ELSLAGER EF et al.: Synthesis, antimalarial activity, and quantitative structure-activity relationships of tebuquine and a series of re-lated 547-chloro-4quinolinyDamino]-3-[(al-kylamino)methyl][1,1'-biphenyl]-2-ols and N°-oxides. J. Med. Chem. (1986) 29:924–939.
   PubMed Web of Science ®Google Scholar
• KESTEN SJ, JOHNSON J, WERBEL LM: Synthesis and anti-malarial effects of 4 -[(7-chloro-4-quinoliny0 amino]-2-[(diethylamino)methyl]-6-alkylphenols and their N°-oxides. J. Med. Chem. (1987) 30:906–911.
   PubMed Web of Science ®Google Scholar
• ENGERS H, GODAL T: Malaria vaccine development: current status. Parasitol. Today. (1998) 14:56–64.
   PubMedGoogle Scholar
• MESHNICK SR, TAYLOR TE, KAMCHONWONGPAISAN S: Artemisinin and the antimalarial endoperoxides: from herbal remedy to targeted chemotherapy. Micro-biol. Rev. (1996) 60:301–315.
   PubMedGoogle Scholar
• HUDSON AT: Atovaquone - a novel broad-spectrum anti-infective drug. Parasitol. Today (1993) 9:66–68.
   PubMedGoogle Scholar
• COATNEY GR: Pitfalls in a discovery: the chronicle of chloroquine. Am. J. Trop. Med. Hyg. (1963) 12:121–128.
   PubMed Web of Science ®Google Scholar
• WERNSDORFER WH: Epidemiology of drug resistance in malaria. Acta Tropica (1994) 56:143–156.
   PubMed Web of Science ®Google Scholar
• ZUCKER JR, CAMPBELL CC: Antimalarial chemotherapy; a relentless challenge. Curr. Opin. Infect. Dis. (1995) 8:455–460.
   Web of Science ®Google Scholar
• WARD SA, BRAY PG, MUNGTHIN M, HAWLEY SR: Current views on the mechanisms of resistance to quinoline-containing drugs in Plasmodium falciparum. Ann. Trop. Med. Parasitol. (1995) 89:121–124.
   PubMed Web of Science ®Google Scholar
• MARTIN SK, ODUOLA AMJ, MILHOUS WK: Reversal of chloroquine resistance in Plasmodium falciparum by verapamil. Science (1987) 235:899–901.
   PubMed Web of Science ®Google Scholar
• GROGL M, MARTIN RK, ODUOLA AMJ, MILHOUS WK, KYLE DE: Characteristics of multidrug resistance in Plasmodium and Leishmania; detection of P-glycoprotein-like components. Am. J. Trop. Med. Hyg. (1991) 45:98–111.
   PubMed Web of Science ®Google Scholar
• FOOTE SJ, KYLE DE, MARTIN RK et al.: Several alleles of the multi-drug resistance gene are closely linked to chloroquine resistance in Plasmodium falciparum. Nature (1990) 345:255–258.
   PubMed Web of Science ®Google Scholar
• VAN ES HHG, KARCZ S, CHU F et al.: Expression of the plasmodial pfmdrl gene in mammalian cells is associ-ated with increased susceptibility to chloroquine. Mol Cell Biol. (1994) 14:2419–2428.
   PubMedGoogle Scholar
• VOLKMAN SK, COWMAN AF, WIRTH DF: Functional complementation of the ste6 gene of Saccharomyces cerevisiae with the pfmdrl gene of Plasmodium falci-parum. Proc. Natl. Acad. Sci. USA (1995) 92:8921–8925.
   PubMedGoogle Scholar
• WELLEMS TE, PANTON LJ, GLUZMAN IY et al.: Chloro-quine resistance not linked to MDR-like genes in a Plasmodium falciparum cross. Nature (1990) 345:253–255.
   PubMed Web of Science ®Google Scholar
• ••Important work defining a genetic locus associated withchloroquine resistance on chromosome 7 of P. falciparum.
   Google Scholar
• SU X-Z, KIRKMAN LA, FUJIKOWA H, WELLEMS TE: Com- plex polymorphisms in an 300 kDa protein are linked to chloroquine-resistant P. falciparum in South-east Asia and Africa. Cell (1997) 91:593–603.
   Google Scholar
• ••Further development of work in ref. 39, pinpointing a par-ticular protein associated with conferring chloroquine-resistance in P. falciparum.
   Google Scholar
• WHITE NJ: Can amodiaquine be resurrected? Lancet (1996) 348:1184–1185.
   PubMed Web of Science ®Google Scholar
• NEFTEL KA, WOODTLY W, SCHMID M, FRICK PG, FEHR J: Amodiaquine induced agranulocytosis and liver dam-age. Br. Med. J. (1986) 292:721–723.
   PubMed Web of Science ®Google Scholar
• HATTON CSR, PETO T, BUNCH C et al.: Frequency of se-vere neutropenia associated with amodiaquine pro-phylaxis against malaria. Lancet (1986) i: 411–413.
   Google Scholar
• TINGLE MD, JEWELL H, MAGGS JL, O'NEILL PM, PARK BK:The bioactivation of amodiaquine by human polymor-phonuclear leucocytes in vitro: chemical mechanisms and the effects of fluorine substitution. Biochem. Phar-macol (1995) 50:1113–1119.
   PubMed Web of Science ®Google Scholar
• NAISBITT DJ, RUSCOE JE, WILLIAMS D, O'NEILL PM, PIR-MOHAMED M, PARK BK: Disposition of amodiaquine and related antimalarial agents in human neutrophils: implications for drug design. J. Pharmacol Exp. Ther. (1997) 280:884–893.
   PubMed Web of Science ®Google Scholar
• OLLIARO P, NEVILL C, LE BRAS J et al: Systematic review of amodiaquine treatment in uncomplicated malaria. Lancet (1996) 348:1196–120.
   PubMed Web of Science ®Google Scholar
• BLOLAND PB, RUEBUSH TK: Amodiaquine. Lancet (1996) 348:1659–1660.
   PubMedGoogle Scholar
• FU S, XIAO S-H: Pyronaridine: a new antimalarial drug. Parasitol Today (1991) 7:310–313.
   PubMedGoogle Scholar
• ••A concise review of early preclinical and clinical data onpyronaridine.
   Google Scholar
• ELUEZE El, CROFT SL, WARHURST DC: Activity of pyro-naridine and mepacrine against twelve strains of Plas-modium falciparum in vitro. J. Antimicrob. Chemother. (1996) 37:511–518.
   PubMed Web of Science ®Google Scholar
• PETERS W, ROBINSON BL: The chemotherapy of rodent malaria. XLVII. Studies on pyronaridine and other Mannich base antimalarials. Ann. Trop. Med. Parasitol. (1992) 86:455–465.
   Google Scholar
• CHANG C, LIN-HUA T, JANTANAVIVAT C: Studies on anew antimalarial compound: pyronaridine. Trans. Royal Soc. Trop. Med. Hyg. (1992) 86:7–10.
   PubMed Web of Science ®Google Scholar
• RING WALD P, BICKII J, BASCO L: Randomised trial of py-ronaridine versus chloroquine for acute uncompli-cated falciparum malaria in Africa. Lancet (1996) 347:24–28.
   PubMedGoogle Scholar
• LOOAREESUVVAN S, KYLE DE, VIRAVAN C, VANIJAN-ONTA S, WILAIRATANA P, WERNSDORFER WH: Clinical study of pyronaridine for the treatment of acute un-complicated falciparum malaria in Thailand. Am. J. Trop. Med. Hyg. (1996) 54:205–209.
   PubMed Web of Science ®Google Scholar
• LOOAREESUVVAN S, OLLIARO P, KYLE D, WERNSDORFER W: Pyronaridine. Lancet (1996) 347:1189–1190.
   Google Scholar
• PETERS W: Pyronaridine against multiresistant P. falci-parum malaria. Lancet (1996) 347:625.
   PubMed Web of Science ®Google Scholar
• RIDLEY RG, HOFHEINZ W, MATILE H et al.: 4 -Aminoquinoline analogues of chloroquine with short-ened side chains retain activity against chloroquine re-sistant Plasmodium falciparum. Antimicrob. Agents Chemother. (1996) 40:1846–1854.
   PubMed Web of Science ®Google Scholar
• •A demonstration that short-chain analogues of chloroquine retain activity against chloroquine-resistant P. falciparum and a detailed preclinical assessment of their potential as an-timalarial drug candidatres.
   Google Scholar
• DE D, KROGSTAD FM, COGSWELL FB, KROGSTAD DJ: Aminoquinolines that circumvent resistance in Plas-modium falciparum in vitro. Am. J. Trop. Med. Hyg. (1996) 55:579–583.
   PubMed Web of Science ®Google Scholar
• •An extension of some of the work in [56], demonstrating that long-chain chloroquine analogues, as well as short-chain analogues, retain activity against chloroquine-resistant P. falciparum.
   Google Scholar
• O'NEILL PM, WILLCOCK DJ, HAWLEY SR et al.: Synthesis,antimalarial activity, and molecular modelling of tebu-quine analogues. J. Med. Chem. (1997) 40:437–448.
   Google Scholar
• O'NEILL PM, HARRISON AC, STORR RC, HAWLEY SR,WARD SA, PARK BK: The effect of fluorine substitution on the metabolism and antimalarial activity of amodia-quine. J. Med. Chem. (1994) 37:1362–1370.
   PubMedGoogle Scholar
• RUSCOE JE, JEWELL H, MAGGS JL et al.: The effect ofchemical substitution on the metabolic activation, metabolic detoxification, and pharmacological activ-ity of amodiaquine in the mouse. J. Pharmacol. Exp. Thar. (1995) 273:393–404.
   PubMedGoogle Scholar
• HAWLEY SR, BRAY PG, O'NEILL P, NAISBIT DJ, PARK BK,WARD SA: Manipulation of the N-alkyl substituent in amodiaquine to overcome the verapamil-sensitive chloroquine resistance component. Antimicrob. Agents Chemother. (1996) 40:2345–2349.
   PubMedGoogle Scholar
• HAWLEY SR, BRAY PG, O'NEILL PM, PARK BK, WARD SA:The role of drug accumulation in 4-aminoquinoline antimalarial potency. The influence of structural sub-stitution and physicochemical properties. Biochem. Pharmacol (1996) 13:723–733.
   Google Scholar
• KOTECKA BM, BARLIN GB, EDSTEIN MD, RIECKMANNKH: New quinoline di-Mannich base compounds with greater antimalarial activity than chloroquine, amo-diaquine, or pyronaridine. Antimicrob. Agents Chemo-ther. (1997) 41:1369–74.
   PubMed Web of Science ®Google Scholar
• BENAZET F: Plasmodium berghei et antimalariques aaction de longue duree. Ann. Soc. Beige. Med. Trop. (1965) 45:459–466.
   Google Scholar
• CHEN L, QU FY, ZHOU YC: Field observations on the an-timalarial piperaquine. Chin. Med. J. (Engl.) (1982) 95:281–286.
   PubMed Web of Science ®Google Scholar
• CHEN L: Recent studies on antimalarial efficacy ofpiperaquine and hydroxypiperaquine. Chin. Med. J. (Engl.) (1991) 104:161–163.
   PubMedGoogle Scholar
• VENNERSTROM JL, ELLIS WY, AGER AL, Jr., ANDERSEN SL, GERENA L, MILHOUS WK: Bisquinolines. 1. N,N-bis(7-chloroquinolin-4-yOalkanediamines with potential against chloroquine-resistant malaria. J. Med. Chem. (1992) 35:2129–2134.
   Google Scholar
• ••A seminal paper demonstrating the activity of some bisqui-nolines against chloroquine-resistant P. falciparum and re-viving interest in this class of compounds.
   Google Scholar
• BASCO LK, ANDERSEN SL, MILHOUS WK, LE BRAS J, VEN-NERSTROM JL: In vitro activity of bisquinoline WR268,668 against African clones and isolates of Plas-modium falciparum. Am. J. Trop. Med. Hyg. (1994) 50:200–205.
   PubMed Web of Science ®Google Scholar
• RIDLEY RG, MATILE H, JAQUET C et al: Antimalarial ac-tivity of the bisquinoline trans-N1,N2-bis (7-chloroquinolin-4-yficyclohexane-1,2-diamine: com-parison of two stereoisomers and detailed evaluation of the 5,5 enantiomer, Ro 47-7737. Antimicrob. Agents Chemother.(1997) 41:677–686.
   PubMed Web of Science ®Google Scholar
• •A detailed preclinical assessment of a bisquinoline antima-larial as a potential drug candidate, highlighting phototoxic-ity as a potential liability for this class of compounds.
   Google Scholar
• RAYNES K, GALATIS D, COWMAN AF, TILLEY L, DEADYLW: Synthesis and activity of some antimalarial bisqui-nolines. J. Med. Chem. (1995) 35:2129–2134.
   Google Scholar
• RAYNES K, FOLEY M, TILLEY L, DEADY LW: Novel bisqui-noline antimalarials. synthesis, antimalarial activity and inhibition of haem polymerisation. Biochern. Phar-macol. (1996) 52:551–559.
   Google Scholar
• ISMAIL FM, DASCOMBE MJ, CARR P, NORTH SE: An explo-ration of the structure-activity relationships of 4-aminoquinolines: novel antimalarials with activity in vivo. J. Pharm. Pharmacol. (1996) 48:841–850.
   PubMedGoogle Scholar
• GO ML, KOH HL, NGIAM TL et al.: Synthesis and in vitroantimalarial activity of some indolo[3,2-c] quinolines. Eur. j Biochem. (1992) 27:391–394.
   Google Scholar
• GORLITZER K, STOCKMANN R, WALTER RD: Antimalar-ial 10H-indolo(3,2-b)quinolin-11-yl-amines. 1. Phenol-Mannich-bases of the amodiaquine and cyclo-quine type. Pharmazie (1994) 49:231–235.
   Google Scholar
• GORLITZER K, STOCKMANN R, WALTER RD: Antimalar-ial active 10H-indolo(3,2-b)quinolin-11-yl-amine. 2. Chloroquine analogs. Pharmazie (1995) 50:105–111.
   Google Scholar
• SWEENEY TR: 8-Aminoquinolines. In: Handbook of Ex-perimental Pharmacology Vol 68/11 Antimalarial Drugs H Peters W, Richards WHG (Eds.), Springer-Verlag (1984) 325–342.
   Google Scholar
• TARLOV AR, BREWER GJ, CARSON PE, ALVIN AG: Pri-maquine sensitivity. Arch. Intern. Med. (1962) 109:209–234.
   PubMed Web of Science ®Google Scholar
• ZHENG XY, CHEN C, GAO FH: Studies on tissue schizon-ticide of malaria parasite: synthesis of 2-substituted benzyloxy (or methoxy)-5-substituted phenoxy ana-logues of primaquine. Yao Hsueh Hsueh Pao (1991) 26:895–901.
   Google Scholar
• ZHONG BH, DENG RX, SHI YL et al: Synthesis of 4-methyl-5-substituted phenoxy-primaquine analogues and preliminary evaluation on their antimalarial ac-tivity. Yao Hsueh Hsueh Pao (1994) 29:268–275.
   Google Scholar
• BATES MD, MESHNICK, SIGLER CI, LELAND P, HOLLING-DALE MR: In vitro effects of primaquine and pri-maquine metabolites on exoerythrocytic stages of Plasmodium bergheL Am. J Trop. Med. Hyg. (1990) 42:532–537.
   Google Scholar
• IDOWU OR, PEGGINS JO, BREWER TG, KELLEY C: Me-tabolism of a candidate 8-aminoquinoline antimalarial agent, WR 238605, by rat liver microsomes. Drug Metab. Dispos. (1995) 1:1–17.
   Google Scholar
• REPORT OF THE COMMITTEE FOR THE STUDY ON MA-LARIA PREVENTION AND CONTROL: Drug discovery and development. In: Malaria, obstacles and opportuni-ties. Oaks SC, Jr., Mitchell VS, Pearson GW, Carpenter CCJ (Eds.), National Academy Press (1991) 159–160.
   Google Scholar
• PETERS W, ROBINSON BL, MILHOUS WK: The chemo-therapy of rodent malaria. LI. Studies on a new 8-aminoquinoline, WR 238,605. Ann. Trop. Med. Parasitol (1993) 87:547–552.
   Google Scholar
• ••A detailed assessment of WR 238,605 (later called etaquine)potency in animal models and its potential as an antimalarial drug candidate.
   Google Scholar
• MILHOUS WK: Etaquine (WR 238605): a promising new8-aminoquinoline. 46th Annual Meeting of the American Society for Tropical Medicine. Lake Buena Vista, Florida (De-cember 1997).
   Google Scholar
• OBALDIA N, 3rd, ROSSAN RN, COOPER RD et al.: WR238605, chloroquine, and their combinations as blood schizonticides against a chloroquine-resistant strain of Plasmodium vivax in Aotus monkeys. Am. J. Trop. Med. Hyg. (1997) 56:508–510
   Google Scholar
• MILHOUS WK: Personal communication
   Google Scholar
• PURI SK, DUTTA GP: Causal prophylactic activity of a new 8-aminoquinoline derivative against Plasmodium cynomolgi B in rhesus monkeys. Indian J Med. Res. (1990) 91:197–199.
   PubMed Web of Science ®Google Scholar
• ••A report demonstrating the potential of CDRI 80/53 as a po-tential primaquine replacement.
   Google Scholar
• SRIVASTAVA P, PURI SK, DUTTA GP, PANDEY VC: Effect of the antimalarial agents primaquine and (Isf-3-acetyl- 4-5 - d hy d r o - 2 - fu r a ny 1)-N4 - (6-met hoxy-8-quinoliny01,4-pentane-diamine on oxidative stress and antioxidant defences in mice. Biochem. Pharmacol (1993) 46:1859–1860.
   PubMedGoogle Scholar
• PURI SK, SRIVASTAVA R, PANDEY VC, SETHI N, DUTTA GP: Methemoglobin toxicity and hematological stud-ies on malaria anti-relapse compound CDRI 80/53 in dogs. Am. J. Trop. Med. Hyg. (1989) 41:638–642.
   PubMedGoogle Scholar
• BHADURI AP: Candidate drugs/products in clinical tri-als. Central Drug Research Institute. Lucknow (1997). An-nual Report 1996–1997, Imam 25
   Google Scholar
• ASTANA OP: Candidate drugs/products in clinical tri-als. Central Drug Research Institute. Lucknow (1997). An-nual Report 1996–1997, Imam 25.
   Google Scholar
• MOCKENHAUPT FP: Mefloquine resistance in Plasmo-dium fakiparum. Parasitol. Today (1995) 11:248–253
   PubMedGoogle Scholar
• DESNEVES J, THORN G, BERMAN A et al.: Photoaffinity labeling of mefloquine-binding proteins in human se-rum, uninfected erythrocytes and Plasmodium falci-parum-infected erythrocytes. Mol. Biochem. Parasitol. (1996) 82:181–194
   PubMedGoogle Scholar
• DE LA CAMPA AG, GARCIA E, FENOLL A, MUNOZ R: Mo-lecular basis of three characteristic phenotypes of Pneumococcus: optochin-sensitivity, coumarin-sensitivity and quinoline-resistance. Microbiol. Drug Resist. 2:177–182.
   Google Scholar
• BIOT C, GLORIAN G, MACIEJEWSKI LA, BROCARD JS: Syn-thesis and antimalarial activity in vitro and in vivo of a new ferrocene compound. J. Med. Chem. (1997) 40:3715–3718.
   PubMed Web of Science ®Google Scholar
• GANTIER JC, FOURNET A, MUNOS MH, HOCQUEMILLER R: The effect of some 2-substituted quinolines isolated from Galipea longitlora on Plasmodium vinckei pet-ten i infected mice. Planta Medica (1996) 62:285–286.
   PubMedGoogle Scholar
• OLLIARO P, WIRTH D: New targets for antimalarial drug discovery. J. Pharm. Pharmacol. (1997) 49 (Suppl. 2):29–33
   Google Scholar
• RIDLEY RG: Plasmodium: drug discovery and develop-ment - an industrial perspective. Exp. Parasitol. (1997) 87:293–304.
   PubMed Web of Science ®Google Scholar
• DREWS J, RYSER S: Pharmaceutical innovation betweenscientific opportunities and economic constraints. Drug Discover)/ Today (1997) 2:365–372.
   Google Scholar